The gut microbiota (GM) is increasingly recognized to play a crucial role in metabolic diseases such as metabolic syndrome (MetS), type 2 diabetes (T2D), dyslipidemia, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). Alterations in GM have been linked to inflammation and pathological deregulation of various metabolic functions, such as glucose and lipid metabolism. Over the past decade, therapies such as fecal microbiota transplantation (FMT) and washed FMT (WMT) have provided some evidence of their therapeutic potential. An increasing amount of scientific evidence has been generated, making it difficult to keep track of the field’s key progress. In this review, we aimed to summarize the scientific progress over the past year on FMT in cardiometabolic diseases. In summary, human and animal studies provide compelling evidence that FMT, depending on various factors, may affect GM to some extent, thereby regulating microbial diversity and metabolic processes. The extent of microbial alterations in recipients and the extent of engraftment of the donor species were particularly crucial factors. Furthermore, in vivo studies provided mechanistic evidence of FMT on the development of T2D, obesity, and cardiovascular disease. Dietary strategies, nutrients, plant compounds, and environmental factors have been linked to the modulation of GM in FMT-based studies.